Trial record 2 of 104 for:
Open Studies | "Cicatrix"
Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars
This study is currently recruiting participants.
Verified February 2013 by Cutera Inc.
Sponsor:
Cutera Inc.
Information provided by (Responsible Party):
Cutera Inc.
ClinicalTrials.gov Identifier:
NCT01789346
First received: February 7, 2013
Last updated: February 11, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and efficacy of the 532nm potassium titanyl phosphate (KTP) laser in comparison with the 595nm pulsed-dye laser (PDL) for the treatment of fresh surgical scars.
| Condition | Intervention | Phase |
|---|---|---|
|
Scar Surgical Scar Cicatrix Cicatrix, Hypertrophic Keloid |
Device: 532nm potassium titanyl phosphate (KTP) laser Device: 595nm pulsed-dye laser (PDL) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Cutera Inc.:
Primary Outcome Measures:
- Comparison of percentage improvement in surgical scar between treatment (532nm KTP laser) and active control (595nm PDL) treatment arms. [ Time Frame: 12-weeks post-final laser treatment ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | February 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
532nm KTP laser
Cutera ExcelV 532nm KTP laser
|
Device: 532nm potassium titanyl phosphate (KTP) laser
Other Names:
|
|
Active Comparator: 595nm PDL
Cynosure Cynergy 595nm pulsed-dye laser
|
Device: 595nm pulsed-dye laser (PDL)
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Fitzpatrick Skin Type I - IV
- Has postoperative linear scar(s) which is one to twelve months post-surgery.
- Having one scar that measures a minimum of 5 cm in length or two scars (bilateral) each measure a minimum of 2 cm in length.
- Be in good health.
- Must agree not to undergo any other procedure for the treatment of scar during the study.
- Willing to refrain from excess sun exposure and willing to wear sunscreen on the treated scar during the study (including the follow-up period).
- Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.
Exclusion Criteria:
- Participation in a study of another device or drug within 6 months prior to enrollment or during the study.
- Having received any prior treatment for the target surgical scar.
- Pregnant and/or breastfeeding.
- Significant concurrent illness, malignant tumors in the target area, acute or chronic skin infection/inflammation, currently using immunosuppressive medications or currently undergoing systemic chemotherapy.
- Current use of any medication known to increase sensitivity to light or taking prescription anticoagulation medication.
- History of abnormal or delayed wound healing, keloid formation or pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
- History of malignant skin disease, immune deficiency disorders, seizure disorders due to light, or diseases stimulated by heat, unless prophylactic measures taken prior to treatment.
- Systemic use of isotretinoin within 6 months or corticosteroids within 12 months of study participation.
- Anytime in life, had used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
- Current smoker or history of smoking within 12 months of study participation.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01789346
Contacts
| Contact: Holly Bryan | 202-628-8855 ext 204 | hbryan@skinlaser.com |
Locations
| United States, District of Columbia | |
| Washington Institute of Dermatologic Laser Surgery | Recruiting |
| Washington, District of Columbia, United States, 20005 | |
Sponsors and Collaborators
Cutera Inc.
More Information
No publications provided
| Responsible Party: | Cutera Inc. |
| ClinicalTrials.gov Identifier: | NCT01789346 History of Changes |
| Other Study ID Numbers: | C-12-EV3 |
| Study First Received: | February 7, 2013 |
| Last Updated: | February 11, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Cutera Inc.:
|
Scar Scars Surgical Scar Surgical Scars Cicatrix Hypertrophic Cicatrix Hypertrophic Scar Scarring |
Keloid Surgical Incision Abdominoplasty Tummy Tuck Augmentation Mammoplasty Breast Augmentation Thyroidectomy |
Additional relevant MeSH terms:
|
Hypertrophy Keloid Cicatrix, Hypertrophic Cicatrix Pathological Conditions, Anatomical |
Collagen Diseases Connective Tissue Diseases Fibrosis Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013